The combination of Lenzilumab Experimental drug and standard Azatsitidin helped cure chronic melonomonocytes. In this aggressive and rare form of blood cancer, remissiah was previously considered unbelievable. The results of the study were published in the "Blood" magazine.
According to scientists, Lenzilumab blocks the main inflammatory alarm, which stimulates the excessive formation of pathological cells. In the first months of treatment, 22 of the 34 patients were significantly reduced to malignant cells and the number of inflammatory markers. The effectiveness has been maintained, and in some cases increased over time.
Fifteen patients remained in the remix more than a year, three for three years. One participant continued to live a normal life without the signs of the relapse for four years. According to Professor Dan Thomas, the head of the study, this is a record for the CST.
In addition, a patient with acute Meloid Leukemia (SML), which was stable to standard therapy, increased Lenzilumab in the proportion of cancer cells to 7% to 7%. This assumes that the approach can be effective in other types of Leukemia.
Although the test is in the early stages, researchers describe the results as "too promising." If the strategy of targeting an inflammatory signal will be established in the future stages.
Translation of: Euromedia24.com
